|
|
|
|
|
|
|
23.12.25 - 21:27
|
Goldman′s Small-Cap Biotech Universe: The 2026 Catalyst Playbook For Investors (ZeroHedge)
|
|
|
Goldman's Small-Cap Biotech Universe: The 2026 Catalyst Playbook For Investors
There are just nine days left in the year, and this year has flown by.
We've delivered readers a steady stream of 2026 outlooks over the past few days and weeks, and next up is a year-ahead catalyst list from Goldman Sachs' small-cap biotech stock coverage.
Goldman analysts, led by Corinne Johnson, held their third "Year-Ahead" Catalyst Clinic, highlighting significant clinical catalysts for small-cap biotech companies (market caps under $3 billion) in their stock coverage universe.
Featured companies in the Catalyst Clinic included AbCellera Biologics, Allogene Therapeutics, Apogee Therapeutics, BioAge Labs, Entrada Therapeutics, Gossamer Bio, Gubra, Lyell Immunopharma, Recursion Pharmaceuticals, Sana Biotechnology, Sionna Therapeutics, Sera Prognostics, Tyra Biosciences, Viralgen, and Viridian Therapeutics.
Johnson said the sentiment from the event was mostly positive, with several names showing cl...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23.12.25 - 02:36
|
Global firms turn to M&A in EVs and biotech to deepen China investment: KPMG (SCMP)
|
|
|
Three in four multinational corporations (MNCs) operating in mainland China have maintained or increased their investments in 2025, according to a recent KPMG survey, despite Washington stepping up efforts to decouple from Beijing and its allies following suit.
The survey published on Monday, polling 137 senior executives from global companies operating in the world's second-largest economy between June and September, revealed that only 1 per cent reported preparing to exit the market. About 20......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
